ListedSMEBook builtNSEBSE

Himalaya Nutravedics IPO

₹100.00 to ₹106.00Price band

Listed on 29 September 2026 at an issue price of ₹106.00.

Subscription and grey market figures refresh on a 30-minute cycle. Last synced 5 October 2026. Confirm current numbers on the exchange websites before you apply.

Issue size
₹26.50 Cr
Lot size
1,200 shares
Minimum investment
₹1,27,200.00
Face value
₹10.00
Fresh issue
₹25.16 Cr
Offer for sale
₹1.34 Cr
Exchanges
NSE and BSE
Bidding dates
22 September 2026 to 24 September 2026

Listed on the exchange

Himalaya Nutravedics priced its issue at ₹106.00 and began trading on 29 September 2026.

The dates that matter

An Indian IPO runs on a fixed calendar. Bidding stays open for three working days, the allotment is finalised the next working day, and the shares begin trading the day after that.

    Issue dates

  1. Anchor investor biddingCompleted

    21 September 2026

    One day before the public window, for institutional anchors.

  2. Bidding opensCompleted

    22 September 2026

  3. Bidding closesCompleted

    24 September 2026

  4. Basis of allotmentCompleted

    25 September 2026

  5. Refunds initiatedCompleted

    28 September 2026

  6. Shares credited to DematCompleted

    28 September 2026

  7. Listing on the exchangeCompleted

    29 September 2026

Grey market premium

No premium was quoted for this issue on any of the 14 days we hold a record for. A blank record is not a premium of zero, and it says nothing about demand either way.

About Himalaya Nutravedics

Himalaya Nutravedics India Ltd. makes and sells Ayurvedic and nutraceutical formulations from Hyderabad, Telangana. The company was incorporated in 2022. It runs two revenue lines: its own branded products and contract manufacturing for other Ayurvedic and nutraceutical firms. Own-brand sales brought in about INR 2,202.54 lakh in FY2026, or 51.14% of total revenue. Products include classical Shastric formulations, proprietary Ayurvedic products and nutraceutical supplements. They come as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. The Hyderabad plant handles formulation, production, quality control, packaging and finished-goods release in-house. It holds WHO-GMP compliance, AYUSH and FSSAI licences, and ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER certifications. Distribution covers several states, with the strongest revenue from Telangana, Andhra Pradesh, Kerala, Gujarat and Uttar Pradesh. The company employed 86 full-time staff as of July 31, 2026.

Promoters

  • Rohit Asawa
  • Divya Asawa
  • Chanda Asawa
  • Rama Raju Penmatsa

Financial highlights

The last three fiscal years as the offer document states them. Reading across a row shows whether the figure has grown, which is why the years run left to right.

Metric (₹ crore)Mar 2024Mar 2025Mar 2026
Assets6.0910.8224.42
Total Income14.4321.0043.12
Profit After Tax0.432.237.39
EBITDA0.942.998.10
NET Worth1.346.7516.38
Reserves and Surplus0.532.7610.07
Total Borrowing3.241.765.13

Figures are in ₹ crore and reproduced from the offer document, covering Mar 2024 to Mar 2026. A dash means the document does not state that figure for that period. A fiscal year ending March is labelled by its closing month, and where the document states a figure on a different basis the label here follows the document rather than normalising it.

Key ratios

Valuation and return ratios calculated from the issuer's financials. These are the figures the issue price is usually judged against, and the offer document carries the working behind each one.

RatioValueWhat it measures
Earnings per share₹11.72Profit after tax divided by the number of shares.
P/E at the cap price9.04xIssue price divided by earnings per share. Lower is cheaper, but only against the same industry.
P/E after the issue12.63xThe same ratio recalculated on the larger post-issue share count.
Price to book3.97xIssue price against net assets per share.
Net asset value per share₹26.70What the company owns, less what it owes, per share.
Return on equity63.87%Profit earned on shareholders’ money.
Return on capital employed36.41%Profit earned on all the capital in the business, including debt.
Return on net worth45.12%The offer document’s own name for return on shareholders’ funds.
Debt to equity0.31xBorrowings against shareholders’ funds. Higher means more leverage.
Profit margin17.16%Profit after tax as a share of income.
Operating margin18.82%Operating profit as a share of income, before interest, tax and depreciation.
Market capitalisation₹93.35 CrValue of the company at the issue price.

Ratios are stated as published. A ratio that is absent here was not stated in the document, and is not the same as a ratio of zero.

What the money is for

Every issue states its objects in the offer document. These are reproduced from it, largest first, so you can see where most of the raise is going.

  • Funding Working Capital Requirements

    ₹13.75 Cr

  • Business Development and Digital Marketing Activities

    ₹7.50 Cr

  • General Corporate Purposes

    ₹3.17 Cr

  • Issue Expenses

    ₹2.08 Cr

Peer comparison

The offer document compares the issuer against listed companies in the same business, on earnings, book value and return on net worth. Himalaya Nutravedics is the first row.

Peer comparison from the offer document. Himalaya Nutravedics is the first row.
CompanyEPS (₹)P/ENAV per share (₹)RoNW
Himalaya Nutravedics India Ltd.This issue12.05—₹26.7045.12%
Jeena Sikho Lifecare Ltd.17.8426.75₹37.6027.67%
Sandu Pharmaceuticals Ltd.1.8320.62₹45.212.53%

Reproduced from the peer comparison in the offer document. A dash means the document does not state that figure for that company. It is absent, not zero. Ratios are reported on the basis named in the document, which is not always the same period for every company.

Who gets what share

SEBI fixes how much of a book-built issue each investor category can be allotted. This is the split for this issue as stated in the offer document.

Reservation by investor category
CategoryShare of issueAmount
Retail individual investors35.09%₹8.83 Cr
Qualified institutional buyers19.97%₹5.02 Cr
Non-institutional (bids above ₹10 lakh)10.01%₹2.52 Cr
Non-institutional (bids up to ₹10 lakh)5.01%₹1.26 Cr

Percentages are reproduced as text from the offer document. A dash means the document does not state an amount for that category. Categories are labelled using the document's own terms, which differ slightly between issues.

Questions people ask

One lot is 1,200 shares. The price band is ₹100.00 to ₹106.00, and the block is calculated at the top of it, ₹106.00. That comes to ₹1,27,200.00 held in your bank account until the allotment is finalised. If you are not allotted, the block is released and the money never leaves your account.

Bidding runs from 22 September 2026 to 24 September 2026. Applications can be revised or withdrawn while bidding is open. Once it closes, the registrar finalises the basis of allotment the next working day and shares are credited the day after.

Retail applications run from 1 lot to 1 lots. The retail category caps an application at ₹2,00,000, so the upper limit is whichever comes first: the lot ceiling or the value ceiling.

We hold the issue price of ₹106.00 and the listing date of 29 September 2026, but our data source does not publish the listing-day open, close or gain, so we cannot state the listing price. The exchange page for this scrip carries the traded price.

Sources